IL17A and neoplasm: Fibroblasts and monocytes stimulated in vitro with IL-17 produce vascular endothelial growth factor (VEGF)-A [19], and IL-17 released in the tumor microenvironment renders tumor resistance to anti-VEGF therapy [20].